These five scaleups stood out to the judges of the 2024 Houston Innovation Awards. Photo via Getty Images

The 2024 Houston Innovation Awards will feature a new category: Scaleup of the Year, which honors a Bayou City company that's seen impressive growth in 2024.

From biotech companies to decarbonization startups, the inaugural finalists have expanded internationally, moved to larger facilities, completed clinical trials and more. Read on to learn more about these fast-growing startups.

Secure your tickets to the 2024 Houston Innovation Awards next Thursday, November 14, at TMC Helix Park.


Cart.com, a unified commerce and logistics solutions provider for B2C and B2B companies

With the acquisition of Amify, Cart.com has expanded its workforce and grown its suite of services. Photo courtesy of Cart.com

Clinching unicorn status with its 2023 series C raise, Cart.com is on a mission to unify commerce across sales and distribution channels and digital and physical capabilities with its omnichannel enterprise-grade software, services and logistics.

Founded in 2020 with nine acquisitions and $759.2 million raised to date, according to Crunchbase, Cart.com's recent achievements includes acquiring Pacsun’s fulfillment operators, brining a 2 million-square-foot facility online, expanding its executive team, and more.

"In the last 12 months, Cart.com has dramatically grown its fulfillment network’s scale and technological capabilities," writes CEO Omail Tariq in his Houston Innovation Awards application.

"We have been laser-focused on improving quality, performance and efficiency at scale while continuing to aggressively grow our customer base, expand our capabilities to customers in new industries and grow our physical presence to new locations," he continues. "Prioritizing our strategic growth initiatives has been critical in the current macroeconomic environment as profitable growth remains paramount for our team."

In 2021, Cart.com moved its headquarters to Austin, with most of the leadership team remaining in Houston. Two years later, the company announced its HQ return to the Bayou City.

"We've found Houston's business and university communities to be incredibly supportive of our efforts and have found the city to be a place that is both easier and more affordable to bring together our global employee population at more regular intervals," Tariq adds in the app.

Coya Therapeutics, a clinical-stage company developing therapies for neurodegenerative, autoimmune, and metabolic diseases

Houston company with revolutionary neurodegenerative disease treatment shares milestones since IPOCoya Therapeutics rang the closing bell at Nasdaq last week, celebrating six months since its IPO, new data from trials, and additions to its team. Photo via LinkedIn

Revolutionary biotech company Coya Therapeutics Inc. (NASDAQ: COYA) may have closed its IPO in January 2023 for more than $15 million, but the company has made some of its most significant strides in the development of its lead product that prevents the further spreading of neurodegenerative diseases this year.

Known as COYA 302, the product uses a unique dual mechanism that is now being developed for the treatment of Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Parkinson’s disease and Alzheimer’s disease. The company published its phase 1 proof-of-concept study in the peer-reviewed journal Frontiers in Neurology that showed COYA 302's ability to stop clinical progression in ALS at 24 weeks in combination therapy, which helped earn the company a $5 million in strategic investment from the Alzheimer’s Drug Discovery Foundation to continue to develop the product for a planned Phase 2 trial focused on FTD.

Last year the company also added to its C Suite, naming Dr. Arun Swaminathan as chief business officer and Dr. Fred Grossman as president and chief medical officer.

Coya merged with Nicoya Health Inc. and raised $10 million in its series A in 2020.

NanoTech Materials, a chemical manufacturer that integrates novel heat-control technology with thermal insulation, fireproofing, and cool roof coatings to drastically improve efficiency and safety

Growing Houston startup moves into 43,000-square-foot facility amid 'hypergrowth phase'NanoTech Materials celebrated its move into a new facility — a 43,000-square-foot space in Katy, Texas, this week

Mike Francis, co-founder and CEO of NanoTech Materials, told InnovationMap earlier this year that it was in a "hype growth" phase—and meant it.

NanoTech, known for its proprietary Insulative Ceramic ParticleTM (ICP) that uses nanotechnology to optimize energy efficiency and heat control in the built environment, expanded into a new 43,000-square-foot facility this year and tripled its valuation in the last two years, according to its Innovation Awards application. The company also expanded into the Middle East and Singapore and successfully scaled up its NanoTech Cool Roof Coat to commercial markets.

The company closed a $5 million seed round in 2020 and an oversubscribed Series A round last year for $13 million. It was the first company selected for the Houston-based Halliburton Labs in 2021 and joined the Rice Alliance Clean Energy Accelerator in 2023.

Square Robot, an advanced robotics company serving the energy industry and beyond by providing submersible robots for storage tank inspections

Square Robot has a team of 15 in Houston. Photo courtesy\u00a0of Square Robot

Submersible robotics company Square Robot launched its Houston office in 2019 and expanded in the Bayou City this past year.

According to the company's Innovation Award application, the company doubled its fleet of autonomous, submersible robots that service the energy industry, deploying to Malaysia, Vietnam, Thailand, Australia, Kuwait and Saudi Arabia. Its robots are specifically used for storage tank inspections and eliminating the need for humans to enter dangerous and toxic environments.

Square Robot moved to a new, customer-facing Houston facility this year and also developed a new innovative technology that's able to gather phased ultrasonic readings on insulated tank shells while the tank is operational.

The company closed a Series A round in 2018 for $6 million.

Syzygy Plasmonics, a company that's decarbonizing chemical production with a light-powered reactor platform that electrifies the production of hydrogen, syngas, and fuel with reliable, low-cost solutions

Houston climatetech startup selected for inaugural global entrepreneur competitionSyzygy Plasmonics is going to be competing in Gastech's new startup competition. Photo courtesy of Syzygy

Known for the world’s first light-powered reactor cell for industrial chemical reactions, Syzygy Plasmonics began taking orders earlier this year for its Rigel reactor cell after meeting initial performance targets. The cell enables a customer to produce up to five tons of low-carbon hydrogen per day.

The groundbreaking technology earned the company regional, national and global attention. Fast Company magazine placed the company on its energy innovation list. It was also named a finalist for Ernst & Young’s Entrepreneur Of The Year 2024 Gulf South Award and was invited to participate in Gastech's global entrepreneur competition.

The company most recently raised $76 million in a Series C round in 2022.

Fannin Partners received two grants to continue developing a new treatment for both addiction medicine and neurodegenerative diseases. Photo via Pexels

Houston firm scores 2 grants to support testing treatment for addiction, neurodegenerative diseases

money moves

A Houston organization devoted to developing early-stage therapeutic and medical device technologies announced fresh funding for one of its startups.

Fannin Partners' Goldenrod Therapeutics, received a $320,000 Phase I SBIR grant from the National Institute on Drug Abuse (NIDA) for studies regarding both addiction medicine and neurodegenerative diseases with a single lead candidate, called 11h.

The grant will fund studies in rodent models of methamphetamine addiction and the efficacy of 11h for the tiny patients. This is the next step in charting the established promise of 11h in substance use disorders using animal models. Existing therapies for opioid and alcohol addiction have high relapse rates, and there are currently no FDA-approved medications for Stimulant Use Disorders (StUDs).

Previous preclinical studies demonstrated that 11h was effective in the fight against cocaine addiction. The goal is to note similar results in methamphetamine addiction.

At the same time, Fannin was also granted a $250,000 Early Hypothesis Development Award from the Department of Defense (DoD) to study 11h in neurodegenerative diseases. Specifically, the funds will be used to work on rodent models of multiple sclerosis (MS).

Fannin’s goal is to develop an oral medication that slows or reverses the progression of MS, while also improving the patient’s quality of life by relieving symptoms. Many MS medications come with the threat of liver injury and increased risk of infection, so sidestepping those is also a hope for 11h.

In fact, 11h was developed to minimize the toxicities associated with existing PDE4 inhibitors. Early evidence shows that the drug is not only effective, but also safe and easily tolerable.

“NIDA’s continued support of our SUD program highlights the potential of 11h to significantly improve the standard of care for patients suffering from these conditions, some of which lack any approved pharmaceutical options," says Dr. Atul Varadhachary, managing partner at Fannin, in a news release. “The additional DoD funding will allow us to explore 11h’s impact on neurodegenerative disease, as well. We are grateful for the support from both organizations as we advance 11h towards clinical development.”

Previous steps in 11h’s development were funded by a $350,000 Phase I SBIR grant from NIDA. 11h is part of NIDA’s Addiction Treatment Discovery Program. Next year, Fannin will likely scale up Good Manufacturing Practices (GMP) production and complete toxicology studies. This will lead to clinical trials for 11h for cocaine use disorder and other StUDs. But don’t expect Fannin to be quiet for long. Its next big discovery is always on the horizon.

This week's episode of the Houston Innovators Podcast revisits a conversation with Howard Berman, co-founder and CEO of Coya Therapeutics. Photo courtesy of Coya

Play it back: Houston therapeutics co. sees momentum with expanded treatment opportunities

houston innovators podcast Episode 253

It's been a busy summer for Houston-based Coya Therapeutics, a clinical-stage biotech company that's creating revolutionary treatments for neurodegenerative diseases like Alzheimer’s, Parkinson’s, and ALS.

In July, Coya announced that has expanded its collaboration with Houston Methodist Research Institute, or HMRI. The publicly traded company also announced fresh funding from the Johnson Center for Cellular Therapeutics.

Last month, Coya reported that it has expanded its treatment research to see how GLP-1 drugs — a trending drug for weight loss — can enhance the effects of its proprietary therapeutics. By combining the medicines, Howard Berman, co-founder and CEO of Coya Therapeutics, says he thinks Coya can better treat these complex immune-based diseases.

Berman joined the Houston Innovators Podcast in April of 2023 to discuss taking Coya public and his passion for the company's mission.

"I was interested in what I could do for my dad," Berman says on the Houston Innovators Podcast, explaining how he took the meeting with Dr. Stanley Appel, who then presented him with some of his research. "By slide five my jaw had hit the ground.

"He had shown that he could stop the progression in one of his early trials of ALS," Berman says.

Berman shares more of the Coya Therapeutics story on the podcast, as well as how he sees Houston's potential as an emerging hub for biotech.

"The next number of years as we develop this therapeutic regimen for ALS, we have the potential to transform Houston into something more than it is currently," he says. "Our success will be the city's success."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

CPRIT hires MD Anderson official as chief cancer prevention officer

new hire

The Austin-based Cancer Prevention and Research Institute of Texas, which provides funding for cancer research across the state, has hired Ruth Rechis as its chief prevention officer. She comes to CPRIT from Houston’s University of Texas MD Anderson Cancer Center, where she led the Cancer Prevention and Control Platform.

Before joining MD Anderson, Rechis was a member of the executive leadership team at the Livestrong Foundation, an Austin-based nonprofit that supports people affected by cancer.

“Ruth has widespread connections throughout the cancer prevention community, both in Texas and across the nation,” CPRIT CEO Kristen Doyle said in a news release. “She is a long-term passionate supporter of CPRIT, and she is very familiar with our process, programs, and commitment to transparency. Ruth is a terrific addition to the team here at CPRIT.”

Rechis said that by collaborating with researchers, policymakers, public health leaders and community partners, CPRIT “can continue to drive forward proven prevention strategies that improve health outcomes, lower long-term costs, and create healthier futures for all.”

At MD Anderson, Rechis and her team worked with more than 100 organizations in Texas to bolster cancer prevention initiatives at clinics and community-based organizations.

Rechis is a longtime survivor of Hodgkin lymphoma, a type of cancer that affects the lymph nodes, which are part of a person’s immune system.

6 female-founded startups shaping the Houston innovation ecosystem

meet the finalists

Female-founded businesses reached a new milestone last year. According to payroll company Gusto, female founders launched 49 percent of new businesses in 2024, reaching near parity with male-founded businesses for the first time.

And though they still face challenges, with access to VC funding at the top of the list, those women-led companies are driving major impact in the startup and innovation ecosystem.

The fifth-annual Houston Innovation Awards will honor six women-led startups that are shaping Houston innovation in our Female-founded Businesses category.

The finalists for the 2025 award, selected by our esteemed panel of judges, range from a company developing natural carbon-free fuel to another launching at-home sleep apnea technology.

Read more about these innovative startups and the visionary female founders behind them below. Then join us at the Houston Innovation Awards on Nov. 13 at Greentown Labs, when the winner will be unveiled at our live awards ceremony.

Tickets are now on sale for this exclusive event celebrating all things Houston innovation.

Anning Corporation

Clean energy company Anning Corporation is working to develop geologic hydrogen, a natural carbon-free fuel, using its proprietary stimulation approaches and advanced exploration modeling. The company said that geologic hydrogen has the potential to be the lowest-cost source of reliable baseload electricity in the U.S.

The company was founded by CEO Sophie Broun in 2024 and is a member of Greentown Labs. Last month, it also announced that it was chosen to participate in Breakthrough Energy’s prestigious Fellows Program. Anning raised a pre-seed round this year and is currently raising a $6 million seed round.

Bairitone Health

Bairitone Health is bringing anatomy imaging for sleep apnea to the home environment. The company's platform maps users' anatomy during natural sleep using a facial patch to determine the root cause of airway obstruction. It then offers effective therapies for each patient. The system is currently in the research and development phase and is being used in clinical trials and studies.

The company was founded in 2022 in the Texas Medical Center's Biodesign program by CEO Meagan Pitcher, CTO Onur Kilic and chief medical officer Britt Cross. It was a member of Activate Houston's inaugural cohort and has participated in numerous accelerators and incubators. It raised a pre-seed round last year of $435,000.

Brain Haven

Founded at the University of Houston, Brain Haven is developing neuroscience-based, clinically validated protocols that use sensory stimulation through smell and sound to offer a natural and non-invasive way to activate the brain and preserve neuroplasticity. The company aims to deliver an accessible and affordable way for the aging population to preserve memory, delay cognitive decline and improve quality of life.

The company was co-founded by Gail Aflalo, a graduate student in the University of Houston College of Optometry, and Jokūbas Žiburkus, an associate professor in the department of biology and biochemistry at UH. It was selected to participate in the 2024 Innov8 Cohort, where it won the cohort's Startup Pitch Day, and was included in Class 13 of UH RED Labs. Brain Haven was awarded $70,000 in seed funding from UH in June 2025 to support a year-long research initiative in adults aged 50 and above.

FlowCare

Sugar Land-based FlowCare is developing a period health platform that integrates smart dispensers, education and healthcare into one system to make free, high-quality organic period products more accessible.

The company was founded by CEO Tanu Jain, a registered nurse and product management executive, in 2024. It participated in the TiE Women Program and the Houston Community College Business Plan Competition, placing in the top five in both pitch competitions.

March Biosciences

Houston cell therapy company March Biosciences aims to treat unaddressed challenging cancers, with its MB-105, a CD5-targeted CAR-T cell therapy for patients with relapsed or refractory CD5-positive T-cell lymphoma, currently in Phase 2 clinical trials.

The company was founded in 2021 by CEO Sarah Hein, Max Mamonkin and Malcolm Brenner and was born out of the TMC Accelerator for Cancer Therapeutics. The company completed a $29.6 million series A last year and also raised a $4.2 million seed round.

TrialClinIQ

Houston-based TrialClinIQ is an AI-powered clinical trial recruitment platform that helps identify, qualify and enroll eligible patients in appropriate trials faster and more accurately.

The company was founded in 2025 by CEO Jontel Pierce and Janette Obi.

-----

The Houston Innovation Awards program is sponsored by Houston Community College, Houston Powder Coaters, FLIGHT by Yuengling, and more to be announced soon. For sponsorship opportunities, please contact sales@innovationmap.com.